{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:40:31Z","timestamp":1766407231381,"version":"3.41.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014389","name":"Amarin Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacl.2025.02.001","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:59:37Z","timestamp":1738828777000},"page":"695-700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of product label vs real-world safety data from branded icosapent ethyl users: A select analysis utilizing MarketScan data"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2455-0296","authenticated-orcid":false,"given":"John R.","family":"Nelson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-5014","authenticated-orcid":false,"given":"Handrean","family":"Soran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilima","family":"Justice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Om P.","family":"Ganda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Abrahamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-3099","authenticated-orcid":false,"given":"Kaveh","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakima","family":"Hannachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sephy","family":"Philip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jacl.2025.02.001_bib0001","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 Heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.jacl.2025.02.001_bib0002","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","article-title":"Determining when to add nonstatin therapy: a quantitative approach","volume":"68","author":"Robinson","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2025.02.001_bib0003","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3949\/ccjm.91a.23058","article-title":"Nonstatin therapy to reduce low-density lipoprotein cholesterol and improve cardiovascular outcomes","volume":"91","author":"Singh","year":"2024","journal-title":"Cleve Clin J Med"},{"year":"2021","series-title":"[Package Insert]","author":"Vascepa","key":"10.1016\/j.jacl.2025.02.001_bib0004"},{"year":"2022","series-title":"[Product Monograph]","author":"Vascepa","key":"10.1016\/j.jacl.2025.02.001_bib0005"},{"year":"2021","series-title":"[Summary of Product Characteristics]","author":"Vazkepa","key":"10.1016\/j.jacl.2025.02.001_bib0006"},{"key":"10.1016\/j.jacl.2025.02.001_bib0007","unstructured":"Vazkepa Australian prescription medicine decision summaries. 2022. Available at: https:\/\/www.tga.gov.au\/resources\/auspmd\/vazkepa. Accessed: June 7, 2023."},{"issue":"5","key":"10.1016\/j.jacl.2025.02.001_bib0008","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: results from the 3,146 patients randomized in the United States","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2025.02.001_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2025.02.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.006589","article-title":"Comparability of event adjudication versus administrative billing claims for outcome ascertainment in the DAPT study: findings from the EXTEND-DAPT study","volume":"14","author":"Faridi","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.1016\/j.jacl.2025.02.001_bib0011","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jamacardio.2017.1460","article-title":"Accuracy of medical claims for identifying cardiovascular and bleeding events after myocardial infarction: a secondary analysis of the TRANSLATE-ACS study","volume":"2","author":"Guimar\u00e3es","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2025.02.001_bib0012","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40261-024-01417-4","article-title":"Evaluating the real-world safety of icosapent ethyl versus omega-3 polyunsaturated fatty acid in nationwide US Veterans cohort: examining atrial fibrillation and bleeding endpoints","volume":"45","author":"Patil","year":"2025","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jacl.2025.02.001_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/20420986221125006","article-title":"Pharmacovigilance: reporting requirements throughout a product's lifecycle","volume":"13","author":"Lucas","year":"2022","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jacl.2025.02.001_bib0014","unstructured":"Guidance for Industry Adverse reactions section of labeling for human prescription drug and biological products - content and format 2006. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/adverse-reactions-section-labeling-human-prescription-drug-and-biological-products-content-and. Accessed: July 3, 2024."},{"issue":"1","key":"10.1016\/j.jacl.2025.02.001_bib0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","article-title":"Real-world data: a brief review of the methods, applications, challenges and opportunities","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jacl.2025.02.001_bib0016","first-page":"25","article-title":"Real-world evidence: a primer","volume":"37","author":"Dang","year":"2023","journal-title":"Pharmaceut Med"},{"issue":"5","key":"10.1016\/j.jacl.2025.02.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.026756","article-title":"Cardiovascular benefits of icosapent ethyl in patients with and without atrial fibrillation in REDUCE-IT","volume":"12","author":"Olshansky","year":"2023","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287425000066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T01:29:41Z","timestamp":1750901381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287425000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1933287425000066"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2025.02.001","relation":{},"ISSN":["1933-2874"],"issn-type":[{"type":"print","value":"1933-2874"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of product label vs real-world safety data from branded icosapent ethyl users: A select analysis utilizing MarketScan data","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2025.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}